P1.04-20 Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.735
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.04-21 the Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-L1 and BCG Response Prediction

Nature Reviews Urology
Urology
2019English

PD-L1 Expression in Lung Cancer and Its Correlation With Driver Mutations: A Meta-Analysis

Scientific Reports
Multidisciplinary
2017English

PD-L1 Gene Expression in Japanese Lung Cancer Patients

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2012English

Utility of CT Radiomics for Prediction of PD‐L1 Expression in Advanced Lung Adenocarcinomas

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

P1.04-24 Digital Core Needle-Biopsy to Assess PD-L1 Expression in Non-Small Cell Lung Cancer: Optimal Sampling and Need for Re-Biopsy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.17-01 PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients From Brazil

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy